Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics, Inc. - Common Stock (NQ:SRPT)

22.35 +1.28 (+6.07%)
Official Closing Price Updated: 4:15 PM EST, Jan 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Sarepta Therapeutics, Inc. - Common Stock

< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
News headline image
Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Sarepta (SRPT) Stock Gains on FDA News ↗
Sarepta Therapeutics (SRPT) stock is rising higher on Friday thanks to an update concerning its Duchenne muscular dystrophy treatment. 
Via InvestorPlace
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Avidity Biosciences Or Dyne Therapeutics - Read On Raymond James' Rating Skew ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
Where Sarepta Therapeutics Stands With Analysts ↗
Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings within the last quarter: 
Via Benzinga
News headline image
Expert Ratings for Sarepta Therapeutics ↗
Analysts have provided the following ratings for Sarepta Therapeutics (NASDAQ:SRPT) within the last quarter: 
Via Benzinga
News headline image
Investors Search for Clues in Economic Data, Recession Signals ↗
Stocks are extending this morning's quiet losses, as investors continue to keep an eye on signs of an oncoming recession. 
Via Talk Markets
News headline image
Sarepta Reports One Heart Inflammation Case In Duchenne Gene Therapy Trial ↗
 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
The Daily Biotech Pulse: European Backing For Novavax's COVID-19 Shot In Adolescents, Sanofi-GSK's Updated Vaccine Effective Against Omicron, FDA's Clinical Hold On Sarepta's Duchenne Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Sarepta Therapeutics: Q1 Earnings Insights ↗
Sarepta Therapeutics (NASDAQ:SRPT) reported its Q1 earnings results on Wednesday, May 4, 2022 at 04:05 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Earnings Scheduled For March 1, 2022 ↗
Companies Reporting Before The Bell • Precigen (NASDAQ:PGEN) is expected to report earnings for its fourth quarter. • TG Therapeutics (NASDAQ:TGTX) is estimated... 
Via Benzinga
News headline image
Sarepta Bets On GenEdit's Nanoparticles' In $57M Gene Editing Partnership ↗
Sarepta Therapeutics Inc (NASDAQ: SRPT) will pay GenEdit up to  
Via Benzinga
News headline image
Analyst Ratings For Sarepta Therapeutics ↗
Over the past 3 months, 6 analysts have published their opinion on Sarepta Therapeutics (NASDAQ: 
Via Benzinga
News headline image
Sarepta Therapeutics' Shares Plummet Following FDA's Clinical Hold On MOMENTUM Study ↗
The U.S. Food and Drug Administration (FDA) has placed a clinical hold on SRP-5051 (vesleteplirsen), Sarepta Therapeutics' (NASDAQ: SRPT) lead candidate to treat patients with Duchenne muscular... 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Sarepta Therapeutics's Earnings: A Preview ↗
Sarepta Therapeutics (NASDAQ:SRPT) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
The Week Ahead In Biotech (May 1-7): Phathom FDA Decision, Pfizer, Vertex Pharma Lead Earnings News, Ophthalmology Conference Presentations, And More ↗
Biotech stocks posted weekly declines yet again in the week ending April 29, taking cues from the weak broader market sentiment. Big pharma earnings, clinical readouts and pipeline updates moved stocks... 
Via Benzinga
News headline image
7 Potential Biotech Stocks Buyout Targets in 2022 ↗
Drug development is a cumbersome process and M&A is a win-win proposition for both the acquirer and the target company. 
Via InvestorPlace
News headline image
Sarepta Therapeutics Stock Shows Market Leadership With Jump To 85 RS Rating ↗
On Thursdays, Sarepta Therapeutics stock had its Relative Strength (RS) Rating upgraded to 85 from 80 a day earlier. 
Via Investor's Business Daily
News headline image
Tough Slogging Ahead for Investors, Diversification is Important ↗
Speculative small/mid-cap biotech stocks hit new lows this past week with the XBI at a “triple bottom” about the $84 level only 10 points above the March 2020 lows. 
Via Talk Markets
News headline image
Where Sarepta Therapeutics Stands With Analysts ↗
Over the past 3 months, 5 analysts have published their opinion on Sarepta Therapeutics (NASDAQ:SRPT) stock. These analysts are typically employed by large Wall Street banks and... 
Via Benzinga
News headline image
Sarepta Therapeutics: Q4 Earnings Insights ↗
Sarepta Therapeutics (NASDAQ:SRPT) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent Resolution ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Editas Gains On Resolution Of CRISPR Gene Editing Patent Case Editas Medicine... 
Via Benzinga
News headline image
Sarepta Therapeutics's Earnings Outlook ↗
Sarepta Therapeutics (NASDAQ:SRPT) is set to give its latest quarterly earnings report on Tuesday, 2022-03-01. Here's what investors need to know before the announcement. Analysts... 
Via Benzinga
News headline image
The Week Ahead In Biotech (Feb. 27-March 5): Earnings, Multiple Regulatory Decisions Take The Spotlight ↗
Biopharma stocks lock-stepped with the broader market in the week ending Feb. 25 before finishing higher. The trajectory was the same, with the sector declining in the first... 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our... 
Via Benzinga
News headline image
Sarepta Abandons Lysogene-Partnered Pivotal-Stage Gene Therapy Candidate ↗
Sarepta Therapeutics Inc (NASDAQ: SRPT) is walking away from a three-year licensing pact for a rare disease gene therapy candidate, leaving its former partner on... 
Via Benzinga
< Previous 1 2
...
27 28 29 30 31 32 33 34 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.